Related Experiment Video
Updated: Mar 25, 2026
05:46
Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
Published on: January 17, 2019
10.8K
Leiomyomas in patients receiving Tamoxifen
Clinical and Experimental Obstetrics & Gynecology
|January 1, 1994
Summary
Uterine fibroids (leiomyomas) can rapidly grow in breast cancer patients taking Tamoxifen (TAM). Stopping TAM and using Triptorelin is a potential alternative to surgery for managing these fibroids.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Pharmacology
Background:
- Tamoxifen (TAM) is a common endocrine therapy for breast cancer.
- Uterine leiomyomas are benign tumors of the uterus, and their growth can be influenced by hormonal factors.
- Literature reports a limited number of unavoidable laparotomies for uterine leiomyomas in patients on Tamoxifen therapy.
Observation:
- This article presents two cases of breast cancer patients treated with Tamoxifen experiencing rapid uterine leiomyoma growth.
- One patient required an abdominal hysterectomy due to the leiomyomas.
- The second patient discontinued Tamoxifen and initiated Triptorelin therapy for her leiomyomas.
Findings:
- Rapidly growing uterine leiomyomas can occur in patients undergoing Tamoxifen treatment for breast cancer.
- Surgical intervention (hysterectomy) is one management option.
- Conservative management involving Tamoxifen cessation and Triptorelin therapy is a viable alternative.
Implications:
- Clinicians should be vigilant for uterine leiomyoma development or rapid growth in breast cancer patients on Tamoxifen.
- Triptorelin therapy presents a potential non-surgical management strategy, preserving fertility and avoiding major surgery.
- This finding may inform treatment decisions for patients with co-existing uterine leiomyomas and breast cancer.
